A 80735
Latest Information Update: 24 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 02 Feb 2001 Profile reviewed but no significant changes made
- 06 Aug 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 08 Aug 1995 New profile